 Carolyn Lefkowits
Concepts (157)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Genital Neoplasms, Female | 20 | 2023 | 72 | 7.880 |
Why?
| | Cancer Pain | 6 | 2019 | 20 | 3.250 |
Why?
| | Palliative Care | 15 | 2023 | 630 | 3.210 |
Why?
| | Analgesics, Opioid | 7 | 2021 | 789 | 2.240 |
Why?
| | Pain Management | 5 | 2021 | 293 | 1.840 |
Why?
| | Medical Oncology | 8 | 2022 | 229 | 1.640 |
Why?
| | Surgical Oncology | 3 | 2019 | 14 | 1.530 |
Why?
| | Gynecology | 7 | 2020 | 184 | 1.400 |
Why?
| | Hot Flashes | 3 | 2013 | 72 | 1.280 |
Why?
| | Pain, Postoperative | 3 | 2021 | 210 | 0.950 |
Why?
| | Terminal Care | 3 | 2023 | 187 | 0.900 |
Why?
| | Hospice Care | 2 | 2023 | 174 | 0.900 |
Why?
| | Referral and Consultation | 4 | 2017 | 644 | 0.890 |
Why?
| | Opioid-Related Disorders | 5 | 2019 | 415 | 0.800 |
Why?
| | Communication | 3 | 2020 | 754 | 0.670 |
Why?
| | Practice Guidelines as Topic | 2 | 2016 | 1433 | 0.610 |
Why?
| | Attitude of Health Personnel | 3 | 2019 | 990 | 0.590 |
Why?
| | Perinatal Care | 1 | 2016 | 37 | 0.580 |
Why?
| | Uterine Cervical Neoplasms | 1 | 2019 | 215 | 0.570 |
Why?
| | Neoplasms | 2 | 2021 | 2160 | 0.560 |
Why?
| | Palliative Medicine | 1 | 2014 | 13 | 0.500 |
Why?
| | Obstetrics and Gynecology Department, Hospital | 1 | 2014 | 3 | 0.490 |
Why?
| | Oncology Service, Hospital | 1 | 2014 | 14 | 0.490 |
Why?
| | Ambulatory Care | 2 | 2017 | 480 | 0.480 |
Why?
| | Endometrial Neoplasms | 3 | 2020 | 144 | 0.470 |
Why?
| | Female | 30 | 2023 | 61261 | 0.460 |
Why?
| | Cyclohexanecarboxylic Acids | 1 | 2013 | 23 | 0.440 |
Why?
| | Cost of Illness | 1 | 2014 | 255 | 0.440 |
Why?
| | Amines | 1 | 2013 | 41 | 0.440 |
Why?
| | Needs Assessment | 1 | 2014 | 325 | 0.430 |
Why?
| | Oncologists | 3 | 2022 | 31 | 0.430 |
Why?
| | Complementary Therapies | 1 | 2013 | 71 | 0.420 |
Why?
| | gamma-Aminobutyric Acid | 1 | 2013 | 155 | 0.410 |
Why?
| | Analgesics | 1 | 2013 | 159 | 0.400 |
Why?
| | Quality of Life | 6 | 2023 | 2355 | 0.390 |
Why?
| | Health Services Accessibility | 1 | 2016 | 776 | 0.380 |
Why?
| | Education, Medical, Graduate | 1 | 2014 | 399 | 0.370 |
Why?
| | Humans | 33 | 2023 | 118251 | 0.370 |
Why?
| | Hospice and Palliative Care Nursing | 2 | 2022 | 68 | 0.370 |
Why?
| | Employment | 2 | 2021 | 133 | 0.360 |
Why?
| | Middle Aged | 16 | 2021 | 27510 | 0.350 |
Why?
| | Guideline Adherence | 1 | 2014 | 520 | 0.350 |
Why?
| | Prostatic Neoplasms | 2 | 2013 | 939 | 0.330 |
Why?
| | Aged | 12 | 2020 | 19594 | 0.320 |
Why?
| | Epidemics | 2 | 2018 | 70 | 0.290 |
Why?
| | Advance Care Planning | 2 | 2020 | 191 | 0.260 |
Why?
| | Adult | 11 | 2021 | 31324 | 0.240 |
Why?
| | Breast Neoplasms | 2 | 2013 | 1957 | 0.240 |
Why?
| | Aged, 80 and over | 4 | 2020 | 6541 | 0.240 |
Why?
| | Medical Futility | 1 | 2023 | 22 | 0.240 |
Why?
| | Patient Care Team | 2 | 2019 | 521 | 0.230 |
Why?
| | Gynecologic Surgical Procedures | 2 | 2020 | 49 | 0.220 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2019 | 895 | 0.210 |
Why?
| | Retrospective Studies | 7 | 2022 | 12929 | 0.210 |
Why?
| | Antineoplastic Agents, Hormonal | 2 | 2013 | 143 | 0.210 |
Why?
| | Brachytherapy | 2 | 2019 | 102 | 0.200 |
Why?
| | Cohort Studies | 4 | 2021 | 5078 | 0.190 |
Why?
| | Ethics, Medical | 1 | 2020 | 73 | 0.180 |
Why?
| | Enoxaparin | 1 | 2020 | 51 | 0.180 |
Why?
| | Pyridones | 1 | 2020 | 119 | 0.170 |
Why?
| | Radiosurgery | 1 | 2022 | 318 | 0.170 |
Why?
| | Infection Control | 1 | 2020 | 135 | 0.170 |
Why?
| | Young Adult | 5 | 2020 | 10731 | 0.170 |
Why?
| | Hospices | 1 | 2020 | 79 | 0.170 |
Why?
| | Carcinoma, Endometrioid | 1 | 2019 | 47 | 0.170 |
Why?
| | Carcinosarcoma | 1 | 2018 | 17 | 0.170 |
Why?
| | Postoperative Care | 1 | 2020 | 237 | 0.160 |
Why?
| | Uterine Neoplasms | 1 | 2018 | 76 | 0.160 |
Why?
| | Disease-Free Survival | 1 | 2019 | 649 | 0.150 |
Why?
| | Drug Prescriptions | 1 | 2019 | 248 | 0.150 |
Why?
| | beta Catenin | 1 | 2019 | 219 | 0.150 |
Why?
| | Preoperative Care | 1 | 2019 | 332 | 0.150 |
Why?
| | Pyrazoles | 1 | 2020 | 363 | 0.150 |
Why?
| | Cancer Care Facilities | 1 | 2017 | 34 | 0.150 |
Why?
| | Perinatal Death | 1 | 2016 | 23 | 0.150 |
Why?
| | Databases, Factual | 2 | 2019 | 1196 | 0.150 |
Why?
| | Drug and Narcotic Control | 1 | 2016 | 28 | 0.150 |
Why?
| | Cancer Survivors | 1 | 2020 | 201 | 0.140 |
Why?
| | Truth Disclosure | 1 | 2016 | 38 | 0.140 |
Why?
| | Venous Thromboembolism | 1 | 2020 | 233 | 0.140 |
Why?
| | Life Expectancy | 1 | 2016 | 51 | 0.140 |
Why?
| | Survival Analysis | 1 | 2020 | 1262 | 0.140 |
Why?
| | Nausea | 1 | 2016 | 107 | 0.140 |
Why?
| | Anticoagulants | 1 | 2020 | 555 | 0.140 |
Why?
| | Mood Disorders | 1 | 2016 | 119 | 0.140 |
Why?
| | Self Efficacy | 1 | 2019 | 347 | 0.130 |
Why?
| | Hospitalization | 2 | 2014 | 1778 | 0.130 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 347 | 0.130 |
Why?
| | Coronavirus Infections | 1 | 2020 | 338 | 0.130 |
Why?
| | Outpatients | 2 | 2017 | 324 | 0.130 |
Why?
| | Program Evaluation | 1 | 2019 | 838 | 0.130 |
Why?
| | Physician-Patient Relations | 1 | 2019 | 484 | 0.120 |
Why?
| | Brain Neoplasms | 1 | 2022 | 1019 | 0.120 |
Why?
| | Patient Education as Topic | 1 | 2019 | 696 | 0.120 |
Why?
| | Evidence-Based Medicine | 1 | 2018 | 690 | 0.120 |
Why?
| | Stellate Ganglion | 1 | 2013 | 4 | 0.110 |
Why?
| | Clonidine | 1 | 2013 | 22 | 0.110 |
Why?
| | Anxiety | 1 | 2019 | 845 | 0.110 |
Why?
| | Societies, Medical | 1 | 2016 | 701 | 0.110 |
Why?
| | Mass Screening | 1 | 2020 | 1048 | 0.110 |
Why?
| | Symptom Assessment | 1 | 2014 | 123 | 0.110 |
Why?
| | Ovariectomy | 1 | 2013 | 124 | 0.110 |
Why?
| | Hormone Replacement Therapy | 1 | 2013 | 80 | 0.100 |
Why?
| | Nerve Block | 1 | 2013 | 67 | 0.100 |
Why?
| | Tamoxifen | 1 | 2013 | 198 | 0.100 |
Why?
| | Pandemics | 1 | 2020 | 1338 | 0.100 |
Why?
| | Drug Interactions | 1 | 2013 | 351 | 0.100 |
Why?
| | Continuity of Patient Care | 1 | 2014 | 262 | 0.100 |
Why?
| | Ovarian Neoplasms | 1 | 2016 | 420 | 0.100 |
Why?
| | Fellowships and Scholarships | 1 | 2014 | 250 | 0.100 |
Why?
| | Depression | 1 | 2019 | 1133 | 0.100 |
Why?
| | Pain | 1 | 2016 | 736 | 0.100 |
Why?
| | Data Collection | 1 | 2014 | 652 | 0.100 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2018 | 1385 | 0.090 |
Why?
| | Multivariate Analysis | 1 | 2014 | 1469 | 0.090 |
Why?
| | Follow-Up Studies | 2 | 2018 | 4574 | 0.090 |
Why?
| | Adolescent | 4 | 2020 | 18364 | 0.090 |
Why?
| | Colorado | 1 | 2019 | 4178 | 0.090 |
Why?
| | Postoperative Complications | 1 | 2020 | 2230 | 0.090 |
Why?
| | Quality Improvement | 1 | 2016 | 962 | 0.080 |
Why?
| | Logistic Models | 1 | 2014 | 1896 | 0.080 |
Why?
| | Chemoradiotherapy | 2 | 2020 | 199 | 0.080 |
Why?
| | Radiotherapy, Adjuvant | 2 | 2019 | 189 | 0.080 |
Why?
| | Curriculum | 1 | 2014 | 908 | 0.080 |
Why?
| | Surveys and Questionnaires | 1 | 2019 | 4684 | 0.070 |
Why?
| | United States | 3 | 2020 | 12488 | 0.070 |
Why?
| | Severity of Illness Index | 1 | 2014 | 2659 | 0.070 |
Why?
| | Male | 4 | 2020 | 57474 | 0.070 |
Why?
| | Infant, Newborn | 1 | 2016 | 5230 | 0.070 |
Why?
| | Neoplasm Staging | 2 | 2019 | 1221 | 0.060 |
Why?
| | Risk Factors | 2 | 2019 | 8958 | 0.060 |
Why?
| | Case-Control Studies | 2 | 2021 | 3156 | 0.060 |
Why?
| | Cranial Irradiation | 1 | 2022 | 69 | 0.050 |
Why?
| | Health Benefit Plans, Employee | 1 | 2020 | 20 | 0.050 |
Why?
| | Unemployment | 1 | 2020 | 42 | 0.050 |
Why?
| | Resource Allocation | 1 | 2020 | 38 | 0.050 |
Why?
| | Standard of Care | 1 | 2020 | 63 | 0.040 |
Why?
| | Poly-ADP-Ribose Binding Proteins | 1 | 2019 | 23 | 0.040 |
Why?
| | Microsatellite Instability | 1 | 2019 | 31 | 0.040 |
Why?
| | DNA Polymerase II | 1 | 2019 | 29 | 0.040 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2019 | 80 | 0.040 |
Why?
| | Neoplasm Grading | 1 | 2019 | 257 | 0.040 |
Why?
| | PTEN Phosphohydrolase | 1 | 2019 | 143 | 0.040 |
Why?
| | SEER Program | 1 | 2018 | 205 | 0.040 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2018 | 360 | 0.040 |
Why?
| | Betacoronavirus | 1 | 2020 | 253 | 0.040 |
Why?
| | Critical Care | 1 | 2020 | 488 | 0.030 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2019 | 454 | 0.030 |
Why?
| | Prognosis | 1 | 2022 | 3424 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2019 | 1237 | 0.030 |
Why?
| | Membrane Proteins | 1 | 2019 | 1048 | 0.030 |
Why?
| | Biomarkers, Tumor | 1 | 2019 | 1056 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2017 | 1857 | 0.030 |
Why?
| | Mutation | 1 | 2019 | 3435 | 0.020 |
Why?
| | Risk Assessment | 1 | 2017 | 3043 | 0.020 |
Why?
| | Pregnancy | 1 | 2020 | 5671 | 0.020 |
Why?
| | Prospective Studies | 1 | 2017 | 6443 | 0.020 |
Why?
|
|
Lefkowits's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|